Core Insights - The company reported a revenue of 32.664 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 3.77%, and a net profit attributable to shareholders of 2.748 billion yuan, up 7.24% year-on-year [1] - The company significantly increased its R&D investment to 2.186 billion yuan, a year-on-year increase of 35.99%, with direct R&D expenses reaching 1.767 billion yuan, up 53.76% [1] - The company achieved a revenue of 10.989 billion yuan in Q3 2025, a growth of 4.53%, and a net profit of 933 million yuan, up 7.71% year-on-year [1] Revenue and Profit Growth - The pharmaceutical industrial segment achieved a revenue of 11.045 billion yuan from January to September 2025, with a year-on-year growth of 11.10%, and a net profit of 2.475 billion yuan, up 15.62% [1] - In Q3 2025, the pharmaceutical industrial segment generated a revenue of 3.728 billion yuan, a growth of 14.95%, and a net profit of 894 million yuan, up 18.43% [2] Innovation and R&D - The sales and agency service revenue from innovative products reached 1.675 billion yuan in the first three quarters of 2025, marking a significant increase of 62% year-on-year [2] - The company has made breakthroughs in three core therapeutic areas: endocrinology, oncology, and autoimmune diseases, with over 90 innovative drug pipeline projects in progress [3] - The company received five marketing approvals and six applications accepted in 2025, with 18 INDs approved in China or the U.S. [3] Product Pipeline and Approvals - The company’s first-in-class drug for oncology, Mevanertinib, received approval in October 2025 for treating specific lung cancer patients [3] - The ADC drug HDM2027 received fast track designation from the FDA in October 2025, with IND approval in China [4] - The company is advancing its GLP-1 targeted products, with multiple applications submitted and clinical trials ongoing [4] Industrial Microbiology and Aesthetic Medicine - The industrial microbiology segment saw a revenue growth of 28.48% from January to September 2025, focusing on core business areas such as xRNA raw materials and health materials [5] - In the aesthetic medicine sector, the company aims to become a global leader, enhancing its operational efficiency and expanding its product matrix across various health and beauty domains [6] Future Outlook - The company is committed to a research-driven and patient-centered approach, aiming to accelerate the development and commercialization of innovative global products for sustainable high-quality growth [6]

格隆汇10月27日丨华东医药(000963.SZ)公布三季度报告，前三季营业收入326.64亿元，同比增长 3.77%，归属于上市公司股东的净利润27.48亿元，同比增长7.24%，归属于上市公司股东的扣除非经常 性损益的净利润26.9亿元，同比增长8.53%。 ...

Core Insights - The company reported steady revenue and profit growth for the first three quarters of 2025, with total revenue reaching 32.664 billion yuan, a year-on-year increase of 3.77%, and net profit attributable to shareholders of 2.748 billion yuan, up 7.24% [1] - Significant investment in R&D was noted, with expenditures rising to 2.186 billion yuan, a 35.99% increase, indicating a strong commitment to innovation [1] - The company’s innovative products are increasingly contributing to revenue, with sales from innovative products reaching 1.675 billion yuan, a substantial growth of 62% year-on-year [2] Financial Performance - For the first nine months of 2025, the pharmaceutical industrial segment achieved revenue of 11.045 billion yuan, a growth of 11.10%, and net profit of 2.475 billion yuan, up 15.62% [2] - In Q3 2025, the segment reported revenue of 3.728 billion yuan, a 14.95% increase, and net profit of 894 million yuan, an 18.43% rise [2] - The company maintained a resilient operational performance despite increased R&D investments, with quarterly revenue and profit showing a consistent upward trend [1] Product Development and Innovation - The company has made significant advancements in its core therapeutic areas, including endocrine, oncology, and autoimmune diseases, with over 90 innovative drug pipeline projects underway [4] - The ADC drug pipeline has shown promising progress, with several candidates receiving IND approvals in both China and the U.S. [5] - The company is preparing for negotiations regarding national medical insurance and commercial insurance for three innovative products, aiming to enhance drug accessibility and drive sales growth [3] Market Position and Strategy - The company has established a strong market presence with its CAR-T product, achieving significant order volumes that exceed previous year's totals [2] - The company’s innovative drug candidates are positioned to address various conditions, including diabetes and cancer, with several products nearing market entry [6][7] - The industrial microbiology segment has also shown robust growth, with a 28.48% increase in revenue, indicating a diversified growth strategy [9] Future Outlook - The company aims to continue its focus on research-driven, patient-centered approaches to foster sustainable high-quality growth [11] - The medical aesthetics business is expected to enhance its brand effect and core competitiveness through a global product matrix [10] - The ongoing development of innovative products and the expansion of market access are anticipated to provide solid momentum for future performance [11]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 第十一届董事会第四次会议决议公告 华东医药股份有限公司 证券代码：000963 证券简称：华东医药 公告编号：2025-097 1、审议通过《关于公司<2025年第三季度报告>的议案》 经审议，董事会认为《2025年第三季度报告》的内容真实、准确、 完整地反映了公司2025年第三季度经营的实际情况，不存在任何虚假 记载、误导性陈述或者重大遗漏，报告编制和审核的程序符合法律、 行政法规和中国证监会的相关规定。具体内容详见公司同日披露于巨 潮资讯网（www.cninfo.com.cn）的公司《2025年第三季度报告》。 表决结果：11票同意，0票反对，0票弃权。 1 该议案已经公司第十一届董事会审计委员会2025年第三次会议 审议通过。 2、审议通过《关于修订<内部审计管理制度>的议案》 华东医药股份有限公司（以下简称"公司"）第十一届董事会第四 次会议的通知于2025年10月23日以书面和电子邮件等方式送达各位 董事，于2025年10月27日（星期一）在公司会议室以现场并结合通讯 方式召开。 ...

Core Viewpoint - Huadong Medicine (000963) reported a steady growth in revenue and net profit for Q3 2025, indicating a positive performance trajectory in the pharmaceutical industry [1] Financial Performance - Q3 2025 revenue reached 10.989 billion yuan, a year-on-year increase of 4.53% [1] - Q3 2025 net profit was 933 million yuan, reflecting a year-on-year growth of 7.71% [1] - For the first three quarters of 2025, total revenue was 32.664 billion yuan, up 3.77% year-on-year [1] - Net profit for the first three quarters of 2025 stood at 2.748 billion yuan, with a year-on-year increase of 7.24% [1] - Basic earnings per share were reported at 1.5682 yuan [1] Product and Service Performance - Revenue from innovative product sales and agency services grew by 62% year-on-year [1] - The core subsidiary of the pharmaceutical industrial sector, Sino-American Huadong, saw a net profit increase of 15.62% year-on-year [1]

Core Viewpoint - Huadong Medicine (SZ 000963) announced the convening of its 11th fourth board meeting on October 27, 2025, to review the proposal for revising the "Internal Audit Management System" [1] Financial Performance - For the first half of 2025, Huadong Medicine's revenue composition was as follows: Commercial brokerage and agency accounted for 68.23%, pharmaceutical manufacturing for 33.94%, medical aesthetics for 4.57%, and other businesses for 0.77%, with inter-segment eliminations at -7.5% [1] Market Capitalization - As of the report, Huadong Medicine's market capitalization stood at 70 billion yuan [1]

Financial Performance - The company's operating revenue for the third quarter reached ¥10,989,214,170.47, representing a year-on-year increase of 4.53%[5] - Net profit attributable to shareholders was ¥933,089,158.25, up 7.71% compared to the same period last year[5] - The basic earnings per share increased by 8.45% to ¥0.5389, while diluted earnings per share rose by 7.41% to ¥0.5320[5] - For the first nine months of 2025, the company achieved operating revenue of RMB 32.664 billion, a year-on-year increase of 3.77%[14] - The net profit attributable to shareholders for the same period was RMB 2.748 billion, up 7.24% year-on-year[14] - The net profit for Q3 2025 was RMB 933 million, representing a year-on-year growth of 7.71%[14] - Total operating revenue for the period reached ¥32,664,143,135.68, an increase of 3.79% compared to ¥31,477,654,750.50 in the previous period[44] - Total operating costs amounted to ¥29,289,598,185.10, up from ¥28,288,811,654.13, reflecting a year-over-year increase of 3.54%[44] - Operating profit for the period was ¥3,350,590,171.04, compared to ¥3,215,352,175.02 in the previous period, indicating a growth of 4.20%[44] - The total profit for the current period is approximately 3.26 billion, an increase from 3.13 billion in the previous period, representing a growth of about 4.1%[45] - The net profit for the current period is approximately 2.74 billion, compared to 2.56 billion in the previous period, reflecting an increase of about 7%[45] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥39,928,783,200.48, reflecting a 5.41% increase from the end of the previous year[5] - Total assets reached ¥39,928,783,200.48, up from ¥37,879,046,367.15, marking an increase of 5.43%[43] - Total liabilities increased to ¥15,432,449,103.14 from ¥14,315,291,455.03, representing a rise of 7.82%[43] - The company’s equity attributable to shareholders increased by 4.65% to ¥24,132,887,034.31 compared to the previous year[5] - Equity attributable to shareholders of the parent company rose to ¥24,132,887,034.31, compared to ¥23,060,051,397.36, an increase of 4.65%[44] Research and Development - Research and development expenses surged by 58.92% to ¥150,759.08, indicating increased investment in innovation[9] - R&D investment in the pharmaceutical industry reached 2.186 billion yuan, a year-on-year increase of 35.99%, with direct R&D expenses accounting for 16.21% of pharmaceutical industrial revenue[20] - The company is advancing over 90 innovative drug pipeline projects, focusing on endocrine, autoimmune, and oncology treatment areas[20] - The application for the first-in-class drug HDM2005 targeting ROR1 is currently in clinical trials, with significant progress reported in multiple studies[22] - The company’s IND application for the oral GLP-1 receptor agonist HDM1002 has been approved, with ongoing clinical trials for weight management and type 2 diabetes[24] Innovative Products and Market Performance - The core subsidiary, China Medical East, reported operating revenue of RMB 11.045 billion, reflecting a growth of 11.10%[14] - The sales revenue from innovative products and agency services reached RMB 1.675 billion, a significant increase of 62% year-on-year[15] - The company’s innovative product, Somatropin injection (brand name: ELAHERE®), generated over RMB 45 million in sales during the first nine months of 2025[16] - The CAR-T product, Zewokiorun injection (brand name: Sikeize®), saw a substantial increase in market penetration with 170 effective orders placed, surpassing the total orders from the previous year[16] - The innovative product sales are expected to continue contributing positively to the overall revenue growth in the upcoming quarters[15] Cash Flow and Financial Management - Cash flow from investment activities showed a net outflow of ¥107,839.19, a 32.79% improvement compared to the previous period[9] - Cash flow from operating activities for the current period is approximately 2.61 billion, compared to 2.51 billion in the previous period, showing an increase of about 4.2%[47] - Cash flow from investing activities for the current period is negative at approximately -1.08 billion, an improvement from -1.60 billion in the previous period[48] - Cash flow from financing activities for the current period is negative at approximately -2.36 billion, worsening from -1.16 billion in the previous period[48] Market Challenges and Segment Performance - The medical aesthetics segment reported revenue of 1.568 billion yuan, a decline of 17.90% year-on-year, reflecting pressure from global economic adjustments and intensified competition[18] - The industrial microbiology segment maintained rapid growth with a revenue increase of 28.48% year-on-year in the first nine months of 2025[19] - Guizhou Company achieved revenue of 172 million yuan in the first nine months of 2025, a year-on-year increase of 194%[17] - Net profit for Guizhou Company reached 53 million yuan, up 489% year-on-year, indicating a continuous improvement in profitability[17] Regulatory Approvals and Partnerships - The company has achieved five product approvals and six acceptances for marketing applications in 2025, along with 18 IND approvals in China or the U.S.[31] - The company has entered into an exclusive commercialization agreement for VC005 with Jiangsu Weikail Pharmaceutical Technology Co., Ltd., granting rights for the oral formulation in mainland China[37] - The company has established an exclusive commercialization partnership for CXG87, a modified budesonide/formoterol inhalation powder, with Hangzhou Changxi Pharmaceutical Co., Ltd., which is currently in Phase III clinical trials[39] - The company received approval for the supplemental application of HDM3001 for pediatric plaque psoriasis in March 2025, and the marketing authorization application for Crohn's disease was accepted in February 2025[27]

华东医药公告，第三季度营收为109.89亿元，同比增长4.53%；净利润为9.33亿元，同比增长7.71%。前 三季度营收为326.64亿元，同比增长3.77%；净利润为27.48亿元，同比增长7.24%。 ...

第一章 总 则 第一条 为规范华东医药股份有限公司（以下简称"公司"）内部审计工作，推进内部 审计管理体系建设，统筹审计资源，拓展内部审计的广度和深度，依据《华东医药股份有 限公司章程》（以下简称"公司章程"）及《中华人民共和国公司法》《国际审计准则》《国 际内部审计专业实务框架》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》等法规，特制定本制度。 第二条 内部审计提供独立、客观的确认与咨询服务，通过应用系统化、规范化的方 法评价并改善风险管理、控制和治理过程的效果，增加价值，实现经营目标。 华东医药股份有限公司 内部审计管理制度 第三条 内部审计宗旨是健全公司内部控制体系建设，促进企业经营活动的流程化和 规范化，降低经营风险，有效规避违规违纪和舞弊行为的发生。 第四条 本制度适用于公司各内部机构、全资及控股子公司、分公司（含境外企业）、 具有重大影响的参股公司。 第二章 审计机构与人员 第五条 公司设立风险管理与审计部，对董事会负责，向董事会审计委员会报告工作。 风险管理与审计部在监督检查公司业务活动、风险管理、内部控制、财务信息过程中，接 受审计委员会的监督指导。 第六条 内部 ...

Core Viewpoint - The company is actively working on transferring the production of its renal filtration system and related drugs to domestic markets, with ongoing orders and preparations in place for both medical devices and pharmaceuticals [1] Group 1: Medical Devices - The company has received procurement orders for the transcutaneous glomerular filtration rate measurement device (TGFR) from various distributors and medical institutions for research and clinical use [1] - The company has completed inventory preparations with partners in advance for the TGFR device and is planning to transfer production to domestic facilities [1] Group 2: Pharmaceuticals - The company's wholly-owned subsidiary, China-US East, will independently produce and sell the drug Remabizine injection in China [1] - China-US East will also serve as one of the suppliers for MediBeacon in the U.S. market [1]